Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization.

Area of Science:

• Immunology
• Cancer Research
• Vaccinology

Background:

• Transcutaneous peptide immunization (TCI) effectively targets dendritic cells in vivo.
• TCI mimics physiologic conditions during pathogen infection to induce tumor-specific cytotoxic T lymphocytes (CTL).

Purpose of the Study:

• To investigate if including a Th1 peptide in TCI can enhance CTL responses by activating preexisting memory Th1 (mTh1) cells.
• To evaluate the impact of peptide-25, a Th1 epitope from Mycobacterium tuberculosis, on TCI-induced antitumor immunity.

Main Methods:

• Adoptive transfer of peptide-25-specific mTh1 cells and hgp100-specific naive CTL (pmel-1 TCR transgenic) into C57BL/6 mice.
• Transcutaneous immunization with CTL peptide (hgp100) and Th1 peptide (peptide-25).
• Monitoring of pmel-1 cell frequency and function via intracellular IFN-gamma staining, ELISPOT, and in vivo cytotoxicity assays.

Main Results:

• TCI efficiently expanded hgp100-specific, IFN-gamma-producing, cytotoxic CD8(+) T cells.
• Concurrent activation of mTh1 cells by peptide-25 increased hgp100-specific CTL numbers by 1.5-fold with enhanced effector functions.
• TCI demonstrated both prophylactic and therapeutic antitumor responses, augmented by peptide-25.

Conclusions:

• TCI facilitates peptide-specific CD4(+) T cell activation, enhancing CTL responses.
• The findings suggest that TCI combined with Th1 peptide activation could augment antitumor immunity, particularly in populations with existing memory Th1 cells from BCG vaccination.